SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst…
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78MELBOURNE, Australia,…
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is…
PRECISE study to generate pivotal clinical data for the Symani® Surgical System in free tissue transfer and lymphatic surgical repairJACKSONVILLE,…
The Company Reinforces Market Position, Maintaining Comprehensive PPO Portfolio As Clover Assistant Drives Sustainable ValueJERSEY CITY, N.J., Oct. 15, 2025…
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company…
Atlas H&E-TME delivers robust analyses at single-cell resolution in hours BERLIN and NEW YORK, Oct. 15, 2025 /PRNewswire/ -- Following…
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire…
Fondue Restaurant Continues Partnership With Goal of Raising Over $1.5 Million Through Donate & Dine Cards TAMPA, Fla., Oct. 14,…